Perez, Thomas

From:
Sent: Wednesday, April 17, 2002 10:20 PM
To: perezt@cder.fda.gov
Subject: Lotronex input for 4-23-02 Gastrointestinal Drugs Advisory meeting

Dear Mr. Perez,
I see that the re-licensing of Lotronex will be discussed at the next committee meeting. As I live in Phoenix, I will be unable to attend, but would like to have the following information added to the public comments and discussion time. Please let me know is this is possible.

To members of the Gastrointestinal Drugs Advisory Committee Members:

I am a surviving family member of a patient who suffered and died as a result of the side effects of Lotronex. I hope to be the voice for my mother who died a horrible, painful, needless death because of Lotronex's side effects. After reviewing material and documents available to the public from your own committee meetings, I believe that Glaxo-Welcome purposefully misrepresented severe and deadly side effects

of the medication seen in the clinical trials of this medication. Ischemic colitis is a well-documented side effect of this medication. Why would you begin discussions again on licensing such a harmful drug? Would you as physicians knowingly allow your daughter, sister, wife, or mother to take such a risk by taking Lotronex? If the answer is no, then please stop and rethink these discussions about allowing it to be prescribed again. Women will again suffer and die if Lotronex is released. You have the power to stop this deadly drug from killing innocent women. Do the right thing!